Evidence map›Paper›PMID 27859429›Full record

ArticleAlcoholism, clinical and experimental research2016

Tigecycline Reduces Ethanol Intake in Dependent and Nondependent Male and Female C57BL/6J Mice.

Susan E Bergeson, Michelle A Nipper, Jeremiah Jensen, Melinda L Helms, Deborah A Finn

Open access · greenAbstract read
In one paragraph

Article in Alcoholism, clinical and experimental research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Mouse parasubthalamicbioRxiv : the preprint server for biology · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. The Gut Microbiome and Substance Use Disorder.Frontiers in neuroscience · 2021
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Repurposing Tigecycline for the Treatment of Alcohol Use Disorder.Alcoholism, clinical and experimental research · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Susan E BergesonDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, Texas.
Michelle A NipperDepartment of Behavioral Neuroscience, Oregon Health & Science University, Portland, Oregon.
Jeremiah JensenDepartment of Behavioral Neuroscience, Oregon Health & Science University, Portland, Oregon.
Melinda L HelmsDepartment of Behavioral Neuroscience, Oregon Health & Science University, Portland, Oregon.
Deborah A FinnDepartment of Behavioral Neuroscience, Oregon Health & Science University, Portland, Oregon.
Oregon Health & Science University · USTexas Tech University · USVA Portland Health Care System · US

Funding

NEUROSTEROID MODULATION OF ETHANOL WITHDRAWAL SEVERITYR01AA012439 · NIAAA · OREGON HEALTH & SCIENCE UNIVERSITY · PI FINN, DEBORAH A., ROSSI, DAVID J · 2000 to 2017
$4.6M
Neuroimmune Interactions in High Alcohol DrinkingR21AA021142 · NIAAA · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI BERGESON, SUSAN E. · 2013 to 2014
$390k
NIAAA NIH HHS R01 AA012439NIAAA NIH HHS R21 AA021142
6 · The paper itself

Abstract

backgroundThe chronic intermittent ethanol (CIE) paradigm is valuable for screening compounds for efficacy to reduce drinking traits related to alcohol use disorder (AUD), as it measures alcohol consumption and preference under physical dependence conditions. Air control-treated animals allow simultaneous testing of similarly treated, nondependent animals. As a consequence, we used CIE to test the hypothesis that tigecycline, a semisynthetic tetracycline similar to minocycline and doxycycline, would reduce alcohol consumption regardless of dependence status.

methodsAdult C57BL/6J female and male mice were tested for tigecycline efficacy to reduce ethanol (EtOH) consumption using a standard CIE paradigm. The ability of tigecycline to decrease 2-bottle choice of 15% EtOH (15E) versus water intake in dependent (CIE vapor) and nondependent (air-treated) male and female mice was tested after 4 cycles of CIE vapor or air exposure using a within-subjects design and a dose-response. Drug doses of 0, 40, 60, 80, and 100 mg/kg in saline were administered intraperitoneally (0.01 ml/g body weight) and in random order, with a 1-hour pretreatment time. Baseline 15E intake was re-established prior to administration of subsequent injections, with a maximum of 2 drug injections tested per week.

resultsTigecycline was found to effectively reduce high alcohol consumption in both dependent and nondependent female and male mice.

conclusionsOur data suggest that tigecycline may be a promising drug with novel pharmacotherapeutic characteristics for the treatment of mild-to-severe AUD in both sexes.

Indexed as

Alcohol DrinkingAlcoholismAnimalsCase-Control StudiesDose-Response Relationship, DrugFemaleMaleMiceMice, Inbred C57BLMinocyclineTigecyclineMinocyclineTigecyclineAlcohol DependenceAlcoholismChronic Intermittent EthanolMedications DevelopmentTigecycline

Identifiers

PMID27859429
PMCPMC5261828
OpenAlexW2556975427

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.